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ABSTRACT
Abnormal activation of the epidermal growth factor receptor (EGFR) due to a 
deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma 
(GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are 
heterogeneous. To investigate the role for EGFRvIII activation in tumor phenotype we 
used a neural progenitor cell-based murine model of GBM driven by EGFR signaling 
and generated tumor progenitor cells with high and low EGFRvIII activation, pEGFRHi 
and pEGFRLo. In vivo, ex vivo, and in vitro studies suggested a direct association 
between EGFRvIII activity and increased tumor cell proliferation, decreased tumor 
cell adhesion to the extracellular matrix, and altered progenitor cell phenotype. Time-
lapse confocal imaging of tumor cells in brain slice cultures demonstrated blood vessel 
co-option by tumor cells and highlighted differences in invasive pattern. Inhibition 
of EGFR signaling in pEGFRHi promoted cell differentiation and increased cell-matrix 
adhesion. Conversely, increased EGFRvIII activation in pEGFRLo reduced cell-matrix 
adhesion. Our study using a murine model for GBM driven by a single genetic driver, 
suggests differences in EGFR activation contribute to tumor heterogeneity and 
aggressiveness.
INTRODUCTION
Glioblastoma (GBM) is the most common primary 
malignant brain tumor in adults and is characterized 
by intertumoral and intratumoral heterogeneity [1–4], 
including differences in genomic and epigenomic 
alterations [5, 6], invasive phenotype [7], and RTK 
signaling pathway activity [8]. Although gene expression 
analysis of bulk tumor tissue suggests tumors can be 
divided into discrete transcriptionally-defined subgroups 
[6, 9], the analysis of multiple samples from the same 
tumor frequently reveals striking intratumoral diversity 
in gene copy number, mutations, and stem cell signature 
[2-4, 10]. GBM heterogeneity endows this cancer with 
an ability to adapt to and evade the anti-tumor effects of 
nearly any therapy. Thus, despite the development and 
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application of targeted therapeutics based on an improved 
understanding of GBM molecular characteristics [11–15], 
tumor heterogeneity continues to confound efforts for 
improving GBM treatment outcomes.
The most common RTK alteration in GBM is of 
the epidermal growth factor receptor (EGFR) and altered 
EGFR signaling is considered a driver of malignant 
characteristics in up to 45% of tumors. EGFR is frequently 
amplified in GBM [11] and approximately 20-30% of 
amplified tumors express a constitutively active variant of 
EGFR, EGFRvIII or EGFR*, which contains a deletion 
of exons 2-7 [11, 16–20]. Several cancers are driven by 
altered EGFR signaling, yet associations between total 
receptor levels, activation levels, and clinical outcome 
have been mixed [21–23]. In GBM, increased expression 
of EGFR or EGFRvIII are also not clearly associated 
with decreased overall survival [18, 24–27] and a link 
between EGFR activation and outcome in GBM is yet to 
be determined.
EGFR signaling is important to the normal biology 
of neural stem cells (NSCs), and promotes the transition 
from a quiescent to an activated state [28]. In the murine 
postnatal brain, EGFR expression in NSCs is reduced 
upon neuronal lineage commitment. Aberrant activation 
of EGFR in neural and glial progenitor cells, either via 
genetic manipulations or by treatment with exogenous 
ligand, induces aberrant proliferation of cells with glial 
features, and can lead to the formation of tumor-like 
lesions [29–32].
The constitutive activation of EGFR conferred by 
EGFRvIII results in altered signaling relative to ligand-
mediated activation of the full-length receptor with 
respect to activated downstream pathways, intracellular 
signaling molecules, and epigenetic regulators [33–35]. 
Complex cross-talk between signaling pathways in 
human GBM and GBM cell lines can complicate the 
investigation of activation of a single RTK. Using an 
immune competent murine model for glioma, based on the 
genetic manipulation of neural progenitor cells and driven 
by EGFRvIII, we identify the activity level of EGFRvIII 
as a determinant of tumor cell aggressiveness.
RESULTS
Generating tumor progenitor cells with 
differences in EGFRvIII activation
To generate tumor progenitor cell lines exhibiting 
divergent EGFRvIII activation, we used a model for high 
grade astrocytoma developed in mice [36]. In this model 
neural progenitor cells (NPCs) are isolated from the 
subventricular zone of Ink4a/Arf null mice and transduced 
with the human EGFRvIII. This and similar models making 
use of neural stem cells and EGFRvIII overexpression are 
known to produce tumors heterogeneous in growth and 
survival [37, 38]. Lysates from EGFRvIII-transduced cells 
derived from the same pool of parental NPCs revealed 
two lines with divergent EGFRvIII activity as determined 
by Western blotting, denoted line A and line B (Figure 
1A). While both cell lines had increased EGFR activity 
relative to parental NPCs, only line A with high EGFRvIII 
activity had a decrease in expression of the full-length 
endogenous EGFRwt. To generate tumor progenitor cells, 
the two EGFRvIII-transduced lines were transplanted 
intracranially into syngeneic mice and the resulting tumors 
were propagated as tumorspheres in minimal essential 
media in vitro as pEGFRHi and pEGFRLo, respectively 
(Figure 1A).
Following in vivo passage and selection of tumor 
progenitor cells, the relative differences in EGFR activity 
were preserved. pEGFRHi had increased abundance of 
phosphorylated EGFRvIII, as evidenced at Y1173 and 
Y1068 tyrosine residues compared to pEGFRLo (6.5- and 
2.86-fold p-EGFR/total, respectively; p<0.005, n=4). 
Differences in EGFRvIII activation were not due to 
differences in total expression of EGFRvIII or differences 
in cell surface expression of EGFRvIII (Figure 1B and 
1C). pEGFRHi also had increased STAT3 activation (6.89-
fold; p>0.001, n=4), based on Y705 tyrosine residue 
phosphorylation (Figure 1B).
EGFRvIII activity associated with more 
aggressive tumors and gene expression signature
Orthotopic transplants of pEGFRHi and pEGFRLo 
revealed significant differences in tumor growth in 
vivo. While both groups developed signs of tumor by 
42 days post transplant, the median survival of mice 
harboring pEGFRHi cells was 21 days versus 31 days for 
pEGFRLo cells (p<0.0001, n=6) (Figure 2A). The more 
aggressive pEGFRHi resulted in greater tumor burden 
than pEGFRLo even at comparable median survival time 
points. Enumeration of ZsGreen tagged tumor cells by 
fluorescence-activated cell sorting (FACS), revealed an 
8.7-fold increase in pEGFRHi versus pEGFRLo tumor cells 
at respective median survival time points (p=0.001, n=6) 
(Figure 2B) and increased tumor area (p<0.05) (Figure 
2C).
To investigate in vivo gene expression differences 
associated with increased EGFRvIII activity, fluorescently-
tagged tumor cells were isolated by FACS from tumors and 
differential gene expression was determined by microarray 
analysis at median survival ±1 day (Figure 2D). KEGG 
pathway annotation of differentially expressed genes 
identified enrichment of processes related to proliferation 
and DNA repair in pEGFRHi tumors. Conversely, 
processes associated with cell-matrix interactions and 
the glycocalyx were enriched in pEGFRLo tumor cells, 
including ‘cell adhesion molecules’, ‘chondroitin sulfate 
biosynthesis’, and ‘heparan sulfate biosynthesis’. In 
addition, processes associated with a wider range of 
differentiation phenotypes, such as ‘axon guidance’ and 
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‘long-term potentiation’, were also enriched in pEGFRLo 
(Figure 2E).
Increased in vivo tumor burden, as defined by 
increased tumor cell number (Figure 2B), increased 
tumor area (Figure 2C), and enrichment of genes involved 
in DNA replication (Figure 2E) suggested increased 
proliferative capacity in pEGFRHi versus pEGFRLo cells. 
In vitro, pEGFRHi had increased incorporation of EdU 
(p<0.01) and greatly reduced doubling time compared 
to pEGFRLo (Figure 2F and 2G), reflecting an increased 
rate of proliferation. No differences in apoptosis were 
appreciated based on immunohistochemical analysis of 
cleaved caspase 3 in tumors (data not shown).
While EGFRvIII lacks a ligand-binding domain 
and can be activated independent of EGF ligand, 
EGFRvIII can act as a substrate for EGF-activated full-
length EGFR [39]. To assess the role for EGF ligand-
mediated signaling in the two lines, cell growth was 
compared in the absence of exogenous EGF ligand. 
While pEGFRHi maintained a high rate of proliferation, 
the growth of pEGFRLo was decreased three-fold in the 
absence of EGF (Figure 2H). These data suggest that 
the higher expression levels of full-length EGFR in 
pEGFRLo may confer some degree of ligand-mediated 
signaling in these cells that is not appreciated in 
pEGFRHi.
Figure 1: Generation of murine tumor cells with divergent EGFRvIII activity. A. Paradigm for generating murine tumor 
progenitor cells with divergent EGFR activation from Ink4a/Arf-null neural progenitor cells and EGFRvIII transduction. After transduction, 
EGFRvIII-transduced cells were assayed for EGFR expression and activity level using western blot and were subsequently passaged 
through syngeneic mice as intracranial tumors to create the pEGFRHi and pEGFRLo lines. B. Western blot analysis of pEGFRHi (Hi) and 
pEGFRLo (Lo) demonstrating differences in EGFRvIII phosphorylation at pY1068 and pY1173 and Stat3 phosphorylation at pY705. C. 
Analysis of EGFRvIII surface levels on pEGFRHi (Hi) and pEGFRLo (Lo) cells using flow cytometry. Solid histograms represent negative 
controls. Data representative of triplicate experiments.
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Figure 2: EGFRvIII activity associated with more aggressive tumors and gene expression signature. A. Kaplan-Meier 
survival curve comparing survival of mice transplanted with pEGFRHi and pEGFRLo tumor cells. Log-rank test median survival 21 versus 
31 days, respectively (p<0.0001) B. Total number of ZsGreen-tagged tumor cells per brain enumerated by fluorescence-activated cell 
sorting (FACS). C. Area of brain involved by tumor as a percentage of total brain area per section with the greatest tumor. D. Schematic of 
isolation of tumor cells by FACS for microarray analysis. E. Enrichment of KEGG pathway processes in pEGFRHi versus pEGFRLo tumors 
based on in vivo microarray analysis of gene expression in sorted cells. F. In vitro EdU incorporation in pEGFRHi and pEGFRLo following 
a 2-hour pulse. G. In vitro doubling time of pEGFRHi (Hi) and pEGFRLo (Lo) cells. H. Growth of pEGFRHi (Hi) and pEGFRLo (Lo) cells in 
the absence of added EGF ligand relative to growth in EGF-supplemented controls. p<0.05 = *, p<0.01 = **, p<0.001 = ***. Error bars are 
displayed as standard error of mean (SEM). (C) n=4.; (F and H) n=3; (G) pEGFRHi n=54, pEGFRLo n=37.
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Blocked differentiation in EGFRvIII highly 
activated tumor progenitor cells
As compared to pEGFRHi cells, pEGFRLo cells had 
enriched expression of pathways associated with a more 
differentiated phenotype. Given that activation of EGFR 
can drive proliferation of a neural progenitor cells we 
examined the expression of a panel of genes associated 
with neural stem and progenitor cell maturation.
Real-time quantitative PCR demonstrated increased 
expression of the immature stem cell markers Prom1 and 
Id1 in pEGFRHi (Figure 3A). Conversely, expression of 
Figure 3: High EGFRvIII activity is associated with an immature stem cell phenotype and EGFRvIII-dependent block 
in differentiation. A. Gene expression of neural stem and progenitor lineage markers in pEGFRHi relative to pEGFRLo cells by real-
time quantitative PCR. B. Cell surface Prominin-1 expression in pEGFRHi (red) and pEGFRLo (blue) cells. Negative control in gray. Data 
representative of triplicate experiments. C. Protein expression of neuronal and glial differentiation markers 3 days after differentiation in 
pEGFRHi and pEGFRLo cells. D and E. Representative images of GFAP (green) and nestin (red) expression after 7 days of differentiation 
of pEGFRHi (D) and pEGFRLo cells (E). F and G. Representative images of GFAP (green) and nestin (red) expression after 7 days of 
differentiation of pEGFRHi control treated (F) or erlotinib treated (G) cells. H. Percentage of GFAP-expressing pEGFRHi cells after 7 days 
of differentiation in control or erlotinib-treated cells. p<0.05 = *. Scale bars D, E, F, G, = 50 μm. (A) n=3; (C) n=4; (H) n=4.
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genes associated with cellular differentiation, such as 
Tubb3 and Ascl1 (Mash1), were upregulated more than 
40-fold in pEGFRLo. Olig2 and Dlx2 transcripts, genes 
commonly expressed by progenitor cells, were also more 
highly expressed in pEGFRLo compared to pEGFRHi 
(Figure 3A). Consistent with a more undifferentiated 
phenotype, more than 95% of EGFRvIII-activated 
pEGFRHi tumor cells expressed Prominin-1 on their cell 
surface (Figure 3B). In contrast, less than 2% of pEGFRLo 
tumor cells expressed Prominin-1 (Figure 3B).
In cell differentiation assays increased EGFRvIII 
activity in pEGFRHi cells was associated with reduced 
differentiation potential relative to in pEGFRLo cells. The 
pEGFRHi cells retained expression of nestin, a marker 
of immature neural stem and progenitor cells, and had 
decreased expression of glial (O4 and GFAP) and neuronal 
lineage markers (TUJ1/βIII-Tubulin) as compared to 
pEGFRLo cells (Figure 3C). Even after 7 days of culture 
under differentiation conditions pEGFRHi cells appeared 
largely undifferentiated, and displayed a small round cell-
appearance with robust expression of nestin (Figure 3D). 
pEGFRLo cultures, in contrast, contained a significant 
population of GFAP-expressing cells, indicative of glial 
differentiation, and exhibited a bipolar or multipolar 
morphology (Figure 3E).
To determine whether the lower differentiation 
potential of pEGFRHi cells was due to high EGFR 
activation, we examined differentiation in the presence 
or absence of the EGFR tyrosine kinase inhibitor 
erlotinib. After 7 days of culture, pEGFRHi cells with 
EGFR inhibition exhibited increased GFAP expression 
and altered cell morphology, with more elongate cells, 
as compared to control-treated pEGFRHi cells, which 
retained their rounded, clumped morphology (Figure 
3F-3H).
Multicellular co-option of the vasculature in 
EGFRvIII activated tumors
Both pEGFRHi and pEGFRLo tumors were highly 
infiltrative with involvement of the striatum, cerebral white 
matter, and cortex (Figure 4A and 4B), yet the pattern of 
tumor infiltration was different. At the invasive front, 
pEGFRHi tumors formed dense multicellular invasive 
cords of tumor cells (Figure 4C and 4E). In contrast, 
pEGFRLo tumors appeared diffusely infiltrative primarily 
as single cells (Figure 4D and 4F). The pattern of invasion 
was highly stable as 78% (18/23) of pEGFRHi and 84% 
(16/19) of pEGFRLo secondary intracranial tumors retained 
the pattern (Figure 4G). At the invasive tumor front, co-
labeling of tumor cells and blood vessels revealed blood 
vessel co-option in both pEGFRHi and pEGFRLo tumors 
(Figure 4H and 4I). Multicellular clusters of pEGFRHi 
tumor cells were often identified in close association with 
the vasculature.
To model these invasive behaviors ex vivo we 
injected tagged tumor cells into freshly isolated brain 
slices and performed confocal imaging of fluorescently-
tagged tumor cells and lectin-labeled blood vessels. 
At 24 hours both pEGFRHi and pEGFRLo cells readily 
invaded into brain slices and showed preferential co-
option of blood vessels (Figure 5A and 5B). Similar to 
their respective in vivo patterns of invasion, pEGFRHi 
cells generated multicellular clusters (Figure 5A) while 
pEGFRLo cells tended to extend as single cells along the 
vasculature (Figure 5B). Quantification demonstrated 
nearly twice as many blood vessel-associated tumor 
cells per 100 μm length of vessel in pEGFRHi compared 
to pEGFRLo (Figure 5C). To distinguish multicellular 
invasion from local tumor cell proliferation in the highly 
proliferative pEGFRHi cells, we performed time-lapse 
confocal imaging of tumor cells in brain slice cultures 
over 24 hours. Both pEGFRHi and pEGFRLo tumor cells 
invaded along blood vessels, but only pEGFRHi tumor 
cells invaded as multicellular groups of cells (Figure 5D, 
Suppl video 1 (pEGFRHi) and 2 (pEGFRLo)).
Decreased cell adhesion and invasion in 
EGFRvIII highly activated tumor cells
Differences in in vivo and ex vivo invasion exhibited 
by pEGFRHi and pEGFRLo tumor cells suggested EGFRvIII 
activity may influence cell-ECM interactions. Tumor cells 
plated on cell culture plates pre-coated with laminin, 
collagen IV, or fibronectin revealed a marked difference in 
cell adhesion between pEGFRHi and pEGFRLo. Increased 
EGFRvIII activity was associated with a reduced ability 
to adhere to all substrates (Figure 6A-6C). To assess how 
decreased cell adhesion may influence invasion in a 3D 
matrix we utilized an in vitro matrigel invasion assay in 
which the primary components are laminin, collagen IV, 
and enactin/nidogen-1 [40, 41]. While pEGFRLo tumor 
cells were highly invasive even by 16 hours, pEGFRHi 
showed very limited invasion even after 24 hours 
(Figure 6D-6E). Thus, the increased EGFRvIII activity 
in pEGFRHi was associated with reduced adhesion and 
reduced invasion in vitro.
To investigate whether reduced adhesion was due 
to increased EGFRvIII activity, cell adhesion assays were 
performed while modulating EGFR activity. Reduction of 
EGFR activity in pEGFRHi cells, using a 2-hour treatment 
with erlotinib, demonstrated a 2.35-fold increase in 
adhesion to collagen IV (p<0.01, n=6) (Figure 7A-7B). In 
contrast, adhesion was decreased when EGFR activity was 
acutely increased in pEGFRLo cells using the phosphatase 
inhibitor sodium orthovanadate (NaOV) (Figure 7C-7D). 
Importantly, pEGFRLo cell adhesion could be restored 
upon inhibition of EGFR in NaOV-treated cells (Figure 
7E). This increase in pEGFRLo adhesion was accompanied 
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Figure 4: Blood vessel co-option and cohesive versus single cell invasion of tumor cells in vivo. A and B. pEGFRHi (A) and 
pEGFRLo (B) form large, invasive tumors highlighted by hEGFR immunohistochemisty. At the infiltrating tumor edge, pEGFRHi C and 
E. tumor cells form cohesive clusters of invading tumor cells while pEGFRLo D and F. tumor cells exhibit diffuse, single cell invasion 
as demonstrated by representative images of H&E stained (C and D) and hEGFR immunolabeled tumor cells (E and F). G. Stability of 
cohesive and diffuse invasive phenotype in pEGFRHi (Hi) and pEGFRLo (Lo) tumors, respectively. Chi-square test for difference in invasive 
pattern p<0.0001. H and I. Confocal images of blood vessel co-option by pEGFRHi (H) and pEGFRHi (I) tumor cells in vivo. Tumor cells 
labeled by hEGFR (green), blood vessels by isolectin IB4 (red), and nuclei by DAPI (blue). Scale bars: A and B = 500 μm, C-F = 50 μm, 
H and I = 100 μm.
by the restoration of well-organized stress fibers in treated 
cells (Figure 7F-7H).
DISCUSSION
GBM are characterized by their heterogeneity, 
including tumor genetics [6], invasive phenotype [7], 
and RTK signaling activation [8]. This heterogeneity is 
an important prognostic factor in GBM and presents 
a great therapeutic challenge [42]. Murine models for 
GBM provide a controlled genetic background to study 
individual oncogenic events [43], however, there has not 
been a major focus on modeling and studying the impact 
of differences in RTK activity levels [37, 38, 44, 45]. 
The potential importance of RTK activity on disease is 
highlighted by elegant studies examining the cross-talk 
between constitutive versus ligand-dependent EGFR 
signaling. Ligand-induced activation of endogenous EGFR 
Oncotarget79108www.impactjournals.com/oncotarget
phosphorylates EGFRvIII and promotes STAT3 activation, 
but can also disrupt EGFRvIII-induced NFkB signaling 
[39, 46]. Moreover, ligand-independent activation of 
EGFR results in non-canonical EGFR signaling through 
the formation of an EGFR, TBK1, and IRF3 complex, 
downstream effects of which include reduced sensitivity 
to chemotherapy [47]. Using a murine model for glioma, 
we demonstrate EGFRvIII activity-dependent regulation 
of cell differentiation and cell adhesion and associate these 
differences with altered animal survival and in vivo tumor 
growth and invasion. Our results suggest that the activity 
of the EGFR signaling pathway, in addition to the specific 
genetic alteration, is an important determinant of tumor 
aggressiveness.
The more aggressive pEGFRHi tumors exhibited 
both increased proliferation and a more cohesive pattern of 
invasion as compared to pEGFRLo tumors. While increased 
proliferation is a known driver of malignancy, differences 
in invasive pattern may also contribute. Indeed, tumor 
progression following antiangiogenic therapy has been 
associated with a perivascular pro-invasive phenotype 
[48, 49].
Diffuse invasion of tumors cells is a characteristic 
feature of human GBM and contributes to poor prognosis, 
yet the pattern of invasion is heterogeneous [7] suggesting 
the contribution of multiple factors. Even within a 
single patient several patterns can often be observed and 
differences in cell adhesion, proteolysis, and migration 
may all contribute. Blood vessel co-option was prominent 
in pEGFRHi and pEGFRLo tumors, yet pEGFRHi invaded as 
multicellular clusters while the less aggressive pEGFRLo 
invaded as single cells. Single cell invasion of pEGFRLo 
was associated with increased in vitro adhesion and 
increased in vivo expression of genes implicated in cell-
matrix interactions, including integrins and proteoglycans. 
In pEGFRHi, inhibition of EGFR increased cell-matrix 
adhesion and promoted a more differentiated phenotype. 
While the identification of factors downstream of EGFR 
Figure 5: Ex vivo slice cultures demonstrate blood vessel co-option and preferential multicellular clustering by 
pEGFRHi. A and B. Blood vessel co-option by both pEGFRHi and pEGFRLo tumor cells. At 24 hours after injection pEGFRHi cells (A) 
appear as cohesive clusters while pEGFRLo cells (B) exhibit a single-cell pattern. C. Blood vessel co-option in slice cultures quantified as 
tumor cell number/100 μm of blood vessel in pEGFRHi and pEGFRLo slice cultures at 24 hours. D. Time-lapse confocal imaging of invasion 
in brain slice cultures over 24 hours. Arrows highlight invading cells. Tumor cells labeled by hEGFR (A and B) and ZsGreen (D) (green), 
blood vessels by isolectin IB4 (red), and nuclei by DAPI (blue). Scale bars: A and B = 100 μm, D = 20 μm. p<0.01 = **. (C) pEGFRHi n=6, 
pEGFRLo =7. Error bars are displayed as standard error of mean (SEM).
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Figure 6: EGFRvIII highly active tumor cells exhibit decreased cell adhesion and invasion in vitro. A-C. Adhesion of 
pEGFRHi and pEGFRLo cells to collagen IV (A), fibronectin (B), and laminin (C), matrices, expressed as fold-change relative to pEGFRHi. 
D. Representative images of matrigel 3D spheroid invasion assay and quantification of pEGFRHi and pEGFRLo invasion E. at 16hr and 24hr 
normalized to pEGFRHi at 0 hours. Scale bars: A=50 μm. p<0.05 = *, p<0.01 = **, p<0.001 = ***. Error bars are displayed as standard error 
of mean (SEM). (A) n=4, (B and C) n=3, (E) n=4.
Figure 7: EGFRvIII activity dictates adhesion properties in mouse tumor cells. A. Western blot analysis of EGFR activation, 
as demonstrated by phosphorylation at Y1173, in control (Ctrl) and erlotinib (Erl) treated pEGFRHi tumor cells. B. EGFR inhibition 
increases adhesion of pEGFRHi cells to a collagen IV-coated substrate. C. Phosphorylation of EGFR at Y1173 in pEGFRLo cells treated with 
0, 50 μM, and 500 μM of the phosphatase inhibitor sodium orthovanadate (NaOV). D. Reduced adhesion of pEGFRLo cells to collagen IV 
in the presence of increasing concentrations of NaOV. E. NaOV-induced reduction in adhesion to collagen IV is restored by inhibition of 
EGFR by Erl in pEGFRLo cells. H-J. Representative confocal images of phalloidin labeled f-actin (green) and nuclei (blue) in control (H), 
NaOV (I), and NaOV+erlotinib (J) treated pEGFRLo cells 2 hours after plating. p<0.05 = *, p<0.01 = **. Error bars are displayed as standard 
error of mean (SEM). (B) n=6, (D) n=3, (E) n=8. Scale bars F-H = 20 μm. (B, D, E) Representative data from triplicate experiments.
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that mediate cohesive invasion is a focus of future studies, 
it is notable that by gene expression array fibronectin 
(FN1) expression was elevated 5.8-fold in pEGFRHi 
tumors. FN1 has previously been implicated in cohesive 
invasion in glioma and gene knockdown increased cell-
matrix adhesion [50]. In addition, differences in protease 
activity or activation of other receptor tyrosine kinases 
such as MET can have profound influences on tumor cell 
invasion [49, 51].
Abnormal activation of EGFR in neural stem and 
progenitor cells promotes proliferation and is detrimental 
to neuronal cell maturation [29–32]. pEGFRHi exhibited 
profound alterations in progenitor cell phenotype with 
high expression of Prominin-1 and decreased ability to 
differentiate, which was at least partially dependent on EGFR 
activation. In immortalized neural stem cells, EGFRvIII 
expression has previously been associated with decreased 
differentiation, increased focal adhesion disassembly, and 
perivascular invasion in vivo [52]. In addition, a CD133-
expressing subset of EGFRvIII+ glioma cells was shown 
to have increased self-renewal and tumorigenicity [53]. 
While several factors, including homozygous deletion of 
Ink4a/Arf-/- [37], likely contribute to the overall modest 
degree of cell differentiation that we observed, our data 
strengthen the link between abnormal EGFR signaling 
pathway activity and aberrations in cell differentiation.
EGFRvIII is known to be expressed at varying 
levels within a tumor [54, 55] and the regulation of 
extrachromosomal EGFRvIII DNA is a major mechanism 
of treatment resistance [56]. Our data, in a genetically 
controlled background, suggest that the level of 
EGFR activation, not just the total protein levels, is an 
important determinant of tumor cell phenotype. Given the 
complexity of EGFR signaling and the multiple feedback 
loops and regulatory mechanisms [57], several factors may 
contribute to differences in EGFR activity and ultimately 
cellular behavior. These include differences in phosphatase 
activity, cell differentiation [58], receptor endocytosis, 
and the activity of other receptor tyrosine kinases [57]. 
Our data emphasize the importance of signaling pathway 
activity, in addition to the genetic status of EGFR, in 
tumor cell behavior and aggressiveness.
MATERIALS AND METHODS
Cell culture conditions and reagents
Murine neural stem cell and tumorspheres 
were cultured as described previously [36, 59]. Three 
dimensional invasion assays were performed as previously 
described [60]. EGF-dependent growth was calculated 
over three consecutive passages comparing cells cultured 
in defined neurosphere media including fibroblast growth 
factor in the presence and absence of added EGF (20 ng/
ml). For adhesion assays, wells of a 96-well plate were 
coated with 2 μg/cm2 Laminin (Sigma L2020), 10 μg/
cm2 Collagen IV (Sigma C5533) or 5 μg/cm2 Fibronectin 
(Sigma F1141). 1-5x104 cells were plated per well and 
incubated for 2 hours. For assays involving erlotinib and 
sodium orthovanadate (NaOV) drug treatments, 1 μM 
erlotinib, 50 μM NaOV, or 500 μM NaOV was added 
to cell suspension for the 2 hour duration of the assay. 
For adhesion assays using co-treatment of erlotinib and 
NaOV, 1 μM erlotinib and 250 μM NaOV was used. 
Protein lysates were prepared as previously described 
[36]. Protein lysates for studying effects of erlotinib and 
NaOV on EGFR phosphorylation were acquired after 2 
hours of incubation in sphere suspension cultures. Images 
acquired for invasion and adhesion assays were acquired 
using a DMI IL LED Leica microscope (Leica, Germany) 
and quantified using ImageJ 1.48v (http://imagej.nih.gov/
ij/). All antibodies used are described in Table 1.
Tumor cell isolation and RNA isolation
Tumor bearing brains were harvested from six mice 
with each tumor type and the cerebellum and olfactory 
bulbs were removed. The brains were diced finely with a 
razor, dissociated using Worthington’s Papain Dissociation 
System (LK003150) and passed through a 70um filter to 
obtain a single cell suspension. To remove myelin and 
red blood cells the cell suspension was re-suspended in 
35% PercollTM (GE Healthcare) and underlaid with 70% 
PercollTM. Following a 30 minute centrifugation purified 
cells were removed from the interface between the 35% 
and 70% layers and counted for viability. ZsGreen+ tumor 
cells were isolated by FACS using a BD FACSAria III into 
TRIzol Reagent (Ambion Life Technologies, Japan), using 
Dapi to exclude dead cells. Sorted cells were re-suspended 
in TRIzol Reagent (Ambion Life Technologies, Japan) and 
RNA was purified using the RNeasy Mini Kit (Qiagen, 
Germany) according to the manufacturers protocol.
In vivo transplantation
Dissociated cells were transplanted as previously 
described previously [36, 59]. FVB mice (Charles River 
Laboratories, Wilmington, MA) were used for tumor 
microarray profiling experiments.
Immunohistochemistry
Murine tumor tissue for immunohistochemical 
analysis was collected at first sign of tumor growth by 
perfusing mice with 4% paraformaldehyde and postfixed 
overnight in 4% PFA. Following postfixation tissue was 
rinsed in PBS and stored in 70% ethanol until further 
processing. Murine tumor paraffin embedded sections 
were immunostained for hEGFR (Dako) to label 
EGFRvIII-expressing tumor cells. Immunohistochemistry 
was performed according to standard protocols on the 
Ventana Medical Systems Benchmark XT (Ventana 
Medical Systems Inc. Tucson, AR, USA). Histological 
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analysis was performed on hematoxylin and eosin stained 
sections. Tumor area was analyzed on hEGFR-labeled 
sections and quantified in ImageJ 1.48v (http://imagej.
nih.gov/ij/).
Ex vivo invasion and time-lapse imaging
Brains from P7-P21 FVB mice were dissected, 
put in cold aCSF, sectioned using a HM650V vibratome 
(Thermo Fisher scientific, San Jose, CA) at thickness of 
190 μm. Slices were incubated in RT aCSF for 30 mins 
prior to transfer to wells with a MilliCell-CM 40 μm 
membranes (Millipore, Bedford, MA). For live imaging, 
ZsGreen expressing cells were injected underneath the 
slice using a Hamilton syringe (Hamilton, Reno, NV), 
for confocal analysis cells were deposited on top of slices 
using P10 pipette. For live imaging slices were imaged 
after 2 hours of incubation at 37°C, using a Zeiss Observer 
Z1 equipped with a Zeiss Observer XL stage incubator 
(37°C, 5% CO2, humidified air) (Carl Zeiss, Germany) 
and a Yokogawa spinning disc scanning unit (Yokogawa 
electric, Japan). Movies assembled using Zeiss imaging 
software (Carl Zeiss) at a single plane from images 
acquired over 6-8 hours. For confocal analysis, slices 
were fixed using 4% paraformaldehyde in phosphate-
buffer saline 24 hours after tumor cell deposition, for 4-6 
hours. A proteinase K antigen retrieval step was used to 
image hEGFR labeled tumor cells, followed by 1 hour of 
block/permabilization, 24-72 hours incubation in primary 
anti-human EGFR antibody antibody (Dako, Denmark, 
Clone H11) at 4°C, and 2 hours incubation in secondary 
antibodies. Slices were washed in PBS 3-5 times after 
each antibody incubation step. Slices were mounted onto 
Superfrost plus glass slides and mounted using Dako 
Table 1: Antibodies used
Antibody Manufacturer Clone Catalog no Application Concentration
Ms α Phospho 
EGFR Y1068 R&D Systems 338324 MAB3570 WB 1:500
Rb α Phospho 
EGFR Y1173
Cell Signaling 53A5 4407 WB 1:500
Rb α Phospho 
Stat3 Y705
Cell Signaling D3A7 9145 WB 1:1000
Ms α Stat3 Cell Signaling 124H6 9139 WB 1:1000
GAPDH Millipore 6C5 MAB374 WB 1:10000
Dk α Rb HRP GE Healthcare  NA9310V WB 1:5000
Dk α Ms HRP GE Healthcare  NA934V WB 1:5000
Ms α hEGFR Dako H11 M3563 IF, IHC 1:200
Isolectin IB4-568
ThermoFisher 
Scientific
 I21412 IF and live 1:200
Rb α EGFR
Santa Cruz 
Biotechnology  Sc-03 WB 1:200
Ms α Nestin EMD Millipore rat401 MAB353 IF 1:200
Rb α GFAP Dako  Z0334 IF 1:400
Ms α Tuj1 Covance  PRB435P IF 1:400
Rb α Olig2 EMD Millipore  AB9610 IF 1:500
Ms α O4 EMD Millipore  MAB345 IF 1:100
Gt α Rb Alexa 488
ThermoFisher 
Scientific
 A-11008 IF 1:500
Gt α Ms Alexa 568
ThermoFisher 
Scientific
 A-11004 IF 1:500
Abbreviations: Ms, mouse; Rb, rabbit; Dk, donkey; Gt, goat; WB, Western blotting; IF, immunofluorescence; IHC, 
immunohistochemistry
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fluorescent mounting media (Dako, Denmark). Images 
were acquired on a Zeiss LS780 laser confocal microscope 
(Carl Zeiss).
Differentiation assay
Cells were prepared as a single cell suspension in 
normal culture media, 500-1000 cells per well were added 
to a laminin/poly-d-lysine coated 8-well culture slide (BD 
Biocoat 354688, BD biosciences) in 300 μL growth media. 
The culture slides were incubated overnight and the media 
carefully removed and replaced with 300 μL of neurobasal 
(Thermo Fisher) + 2% FBS to induce differentiation. 
For studies using erlotinib, erlotinib (1 μM) or DMSO 
was included in differentiation media. Culture slides 
were incubated for 3 to 7 days, then fixed in 4% PFA. 
After immunolabeling, six images per well were taken 
on a Zeiss Axioimager M1 or a Zeiss LSM780 confocal 
microscope (Carl Zeiss), counted for positivity in ImageJ 
1.48v and averaged.
Visualization of f-actin cytoskeleton
pEGFRLo cells were fixed in 4% PFA 2 hours after 
seeding cells onto laminin/poly-d-lysine coated 8-well 
culture slides (BD biosciences). F-actin was visualized 
using Alexa fluor-546 phalloidin according to the 
manufacturer’s instructions (Thermo Fisher). Cells were 
treated with DMSO, 250 μM NaOV, or 250 μM NaOV + 1 
μM erlotinib for the 2 hour duration of the assay.
Flow cytometry
Cell surface PE-conjugated mouse Prom1 antibody 
(Miltenyi Biotec, France, Clone MB9-3G8) and anti-
human EGFR antibody (Dako, Denmark, Clone H11) 
were used to analyze Prominin-1 and EGFRvIII surface 
expression, respectively. Incubation using EGFR was 
followed by fluorescently tagged secondary incubation. 
Data was acquired using a FACSCalibur or FACSCanto 
flow cytometer (BD biosciences). For EdU incorporation 
assay spheres were cultured for 2 days, incubated with 
2 μM EdU for 2 hours, and labeled using Click-IT EdU 
Assay kit (Thermo Fisher). Cells were analyzed using a 
FACSCalibur flow cytometer (BD biosciences). Data was 
analyzed using FlowJo 10 (Tree star, San Carlos, CA).
RNA isolation, cDNA synthesis and RT-PCR
Cells isolated from mouse brains or dissociated 
tumorspheres from culture were prepared as a single 
cell suspension and re-suspended in an appropriate 
volume of RLT buffer from RNeasy mini kit (Qiagen, 
Germany). RNA was isolated as per the manufacturers 
instructions and quantified using a Nanodrop (Nanodrop 
Technologies Inc., Wilmington, DE) Spectrophotometer. 
Complementary DNA was synthesized using Oligo(dT) 
primers and Superscript III (18080-051, Thermo Fisher 
Scientific). Primers were synthesized by IDT (IDT 
Inc, Coralville, IA). The following primers were used: 
Id1 (Forward (Fw): CCTAGCTGTTCGCTGAAGGC, 
Reverse (Rv): GTAGAGCAGGACGTTCACCT), 
Prom1 (Fw: GACCAGGACTCGGATCAAAGG, 
Rv: TGTACTGCTCCACTACATAGTCA), Nes (Fw: 
AGAGTCAGATCGCTCAGATCC, Rv: GCAGAGT 
CCTGTATGTAGCCAC), Sox2 (Fw: GCGGAGT 
GGAAACTTTTGTCC, Rv: GGGAAGCGTGTACTT 
ATCCTTCT), Olig2 (Fw: TCCCCAGAACCCGA 
TGATCTT, Rv: CGTGGACGAGGACACAGTC), Dlx2 
(Fw: CTACGGCACCAGTTCGTCTC, Rv: CCGTTCACT 
ATTCGGATTTCAGG), Tubb3 (Fw: TAGACCCC 
AGCGGCAACTAT, Rv: GTTCCAGGTTCCAAGTC 
CACC), Ascl1 (Fw: GCAACCGGGTCAAGTTGGT, 
Rv: CAAGTCGTTGGAGTAGTTGGG). Real Time PCR 
was performed on a 7900 HT Fast Real-Time PCR System 
(Thermo Fisher Scientific) using FastStart Universal 
SYBR Green Master (Rox) (049138500011, Roche, 
Switzerland). Ct values were normalized to GAPDH 
Ct values for each individual sample and then averaged 
across experiments.
Microarray profiling and analysis
Expression profiling was conducted by the 
Gladstone Institute Genomics Core Facility using 
Affymetrix Mouse Gene 1.0 ST Array (901169). 
Raw expression data was RMA normalized and Log2 
transformed using Affymetrix Expression Console 
Software. The microarray data have been deposited 
in the GEO database (accession number GSE87332) 
and described in accordance with MAIME guidelines. 
Multiple Experiment Viewer Software (MeV; http://www.
tm4.org/mev/) was used to perform Significance Analysis 
of Microarray (SAM) to determine differentially expressed 
genes between the two tumor types. A 1% false discovery 
rate and 2-fold expression difference was applied. The 
subsequent list of differentially expressed genes were 
analyzed for enriched Kegg Pathways using the Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID).
Ethical statement
All animal work was approved by the UCSF 
institutional care and use committee (IACUC), approval 
number AN105263.
Statistics
All statistics were performed using GraphPad Prism 
6.0 (GraphPad Software, San Diego, CA). The Mann-
Whitney Rank Sum or the Student’s t-test were used to 
determine differences between experimental groups as 
appropriate. The log-rank test was used to compare groups 
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in the Kaplan-Meier survival analysis. Chi-squared test 
was used to compare the frequency of invasive phenotypes 
in Figure 1C.
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